Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$1.72 USD
+0.03 (1.78%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.72 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.72 USD
+0.03 (1.78%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $1.72 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Zacks News
What Makes Immix Biopharma (IMMX) a New Buy Stock
by Zacks Equity Research
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
by Zacks Equity Research
Immix Biopharma, Inc. (IMMX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
by Zacks Equity Research
The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.
Here's Why Immix Biopharma, Inc. (IMMX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Immix Biopharma, Inc. (IMMX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Immix (IMMX) Up on Orphan Drug Tag for AL Amyloidosis Therapy
by Zacks Equity Research
Immix (IMMX) gets ODD designation in the United States for lead candidate NXC-201 for the treatment of amyloid light chain (AL) Amyloidosis.